Resources
MRFF Incubator Grants
This document provides information on Medical Research Future Fund (MRFF) incubator grants. MRFF incubator grants support researchers to create new solutions for significant health challenges.
Gene Technology Ministers’ Meeting communique – July 2021
This document is a summary of the Gene Technology Ministers’ Meeting (GTMM) on Tuesday 20 July 2021.
Financial Assistance to Support the Australian Medical Research and Innovation Priorities 2018–2020
This report presents the financial assistance provided from the Medical Research Future Fund Special Account during the period that the Australian Medical Research and Innovation Priorities 2018-2020 (2018–2020 Priorities) were active, specifically from 8 November 2018 to 6 November 2020.
HCP annual report – 2019–20
This annual report of Hospital Casemix Protocol (HCP) data outlines health statistics received from private health insurers detailing information relating to patient, medical and financial data for the 2019–2020 financial year.
PHDB annual report – 2019–20
This annual report of Private Hospital Data Bureau (PHDB) data outlines health statistics received from private hospitals detailing information relating to patient data for the 2019–2020 financial year.
National Standard Operating Procedures for Clinical Trials in Australia
This publication will help organisations to standardise their procedures for clinical trials in Australia. The standard operating procedures have been agreed to by all states and territories.
National Principles for Teletrials in Australia
This publication will help organisations to better understand the principles for teletrials. The principles have been agreed by all states and territories and apply to all health service staff and volunteers who work on clinical trials.
Changes in HCP and PHDB data specifications – 2021–22
This fact sheet outlines changes in the data specifications for Hospital Casemix Protocol (HCP) and Private Hospital Data Bureau (PHDB) data for the 2021–22 financial year. They took effect on 1 July 2021.
HCP data specifications – Hospital to insurer – 2021–22
The Hospital Casemix Protocol (HCP) data specifications for HCP files for 2021–22 details the financial, clinical and demographic data that hospitals must provide to private health insurers. Private health insurers must then provide this data to us. It took effect from 1 July 2021.
HCP data specifications – HCP1 – Insurer to department – 2021–22
The Hospital Casemix Protocol (HCP) data specification for HCP1 files for 2021–22 details the financial, clinical and demographic data that hospitals must provide private health insurers. Private health insurers must then provide this data to us. They took effect from 1 July 2021.
HCP data specifications – HCP2 – Insurer to department – 2021–22
The Hospital Casemix Protocol (HCP) data specification for HCP2 files for 2021–22 details the financial, clinical and demographic data that hospitals must provide private health insurers. Private health insurers must then provide this data to us. They took effect from 1 July 2021.
GT-Dental data specification – Insurer to department – 2021–22
The Hospital Casemix Protocol (HCP) data specification for General Treatment-Dental files for 2021–22 details the financial, clinical and demographic data that hospitals must provide private health insurers. Private health insurers must then provide this data to us. They took effect on 1 July 2021.
PHDB data specification – Hospital to department – 2021–22
The Private Health Data Bureau (PHDB) data specifications for 2021–22 details the financial, clinical and demographic data that hospitals must provide to us. They took effect from 1 July 2021.
A National Strategy for Clinical Quality Registries and Virtual Registries 2020–2030
This strategy is a roadmap for how the Australian health system will collect and use clinical data to improve patient care.
Draft national clinical quality registry strategy – Consultation summary report
This report is a summary of the feedback we received during the consultation process in 2019. It highlights key themes that informed the final strategy.
HCP and PHDB data submission user guide
This user guide for hospitals and private health insurers explains how to submit Hospital Casemix Protocol (HCP) and Private Hospital Data Bureau (PHDB) data.
HCP and PHDB reporting requirements for hospitals and insurers
This fact sheet outlines the Hospital Casemix Protocol (HCP) and Private Hospital Data Bureau (PHDB) reporting requirements for declared hospitals and registered private health insurers.
Medical Research Commercialisation Landscape Report
This report provides information on the medical research commercialisation landscape in Australia.
Evaluation of the Rapid Applied Research Translation Initiative
This report provides information on the 2020 evaluation of the Medical Research Future Fund’s Rapid Applied Research Translation initiative.
MRFF Monitoring, Evaluation and Learning Strategy
This document outlines the framework for assessing the performance of the Medical Research Future Fund (MRFF). It also aims to establish a learning system to support continued improvements within the MRFF.
Australian Medical Research and Innovation Priorities – Consultation report
Read the responses from public consultation submissions as part of the Australian Medical Research Innovation Priorities 2020–2022.
Tranche 1 submitted evidence
Tranche 1 evidence submitted by the public as part of the calls for evidence in the Natural Therapies Review 2024.
National Consultation of the Australian Medical Research and Innovation Priorities 2020-2022
AMRAB National Consultation of the Australian Medical Research and Innovation Priorities 2020-2022 presentation.
The COVID-19 Vaccines and Treatments for Australia – Science and Industry Technical Advisory Group Terms of reference
The terms of reference sets out the role and purpose of the COVID-19 Vaccines and Treatments for Australia – Science and Industry Technical Advisory Group.
Australia’s COVID-19 Vaccine and Treatment Strategy
Our COVID-19 Vaccine and Treatment Strategy outlines how we are investing in promising vaccines and treatments and how they will be safely, fairly and rapidly delivered to Australians.
Date last updated: